文献速递产科

直接结合抑制血管紧张素II 1型受体激动性自身抗体不影响子宫灌注压降低子代大鼠的出生体重及成年期血压

Inhibition of angiotensin II type 1 receptor agonistic autoantibodies by direct binding does not impact reduced uterine perfusion pressure offspring birthweight and blood pressure at adulthood.
PubMed 文献 · Am J Obstet Gynecol MFM · 2023-03-27

本研究在大鼠子宫灌注压降低(RUPP)子痫前期模型中,于妊娠第14天给予n7AAc(24 µg/d)或溶媒,发现n7AAc治疗未改变RUPP子代雄性或雌性的出生体重,也未改变其成年期平均动脉压和循环血管紧张素II 1型受体自身抗体水平。结论提示围产期n7AAc治疗不损害子代出生体重和生存,但未预防子代心血管风险升高,也未增加该风险。

要点

  • RUPP大鼠妊娠第14天给予n7AAc(24 µg/d)未改变雄性或雌性子代出生体重。
  • n7AAc治疗未改变RUPP子代成年期平均动脉压。
  • RUPP子代循环AT1-AA升高,n7AAc治疗未改变该升高。

核心结论

  • 围产期n7AAc治疗不损害RUPP子代出生体重和生存,但未预防子代心血管风险升高,也未增加该风险。
  • 围产期n7AAc治疗未影响内源性免疫编程,表现为RUPP子代成年雌雄循环AT1-AA均无变化。

研究设计与样本

  • 研究为动物实验,使用Sprague-Dawley大鼠RUPP模型及假手术(sham)模型。
  • 妊娠第14天通过微型渗透泵给予n7AAc(24 µg/d)或溶媒(生理盐水)。
  • 母鼠自然分娩,出生12小时内记录仔鼠体重;仔鼠饲养至16周龄时测量平均动脉压并采血。

主要发现

  • RUPP子代出生体重:n7AAc治疗雄性5.63±0.09 g、雌性5.66±0.14 g,溶媒雄性5.51±0.17 g、雌性5.74±0.13 g,无显著变化。
  • sham子代出生体重:n7AAc治疗雄性5.83±0.11 g、雌性5.64±0.12 g,溶媒雄性5.811±0.15 g、雌性5.40±0.24 g,无显著变化。
  • 成年期平均动脉压:RUPP子代n7AAc治疗雄性133±2 mm Hg、雌性127±3 mm Hg,溶媒雄性142±3 mm Hg、雌性133±5 mm Hg,无变化。
  • 成年期平均动脉压:sham子代n7AAc治疗雄性133±3 mm Hg、雌性135±3 mm Hg,溶媒雄性138±4 mm Hg、雌性130±5 mm Hg,无变化。
  • 循环AT1-AA:RUPP子代溶媒雄性10±2 ΔBPM、雌性14±2 ΔBPM,n7AAc治疗雄性11±2 ΔBPM、雌性11±2 ΔBPM;sham子代溶媒雄性1±1 ΔBPM、雌性-1±1 ΔBPM,n7AAc治疗雄性-2±2 ΔBPM、雌性-2±2 ΔBPM。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preeclampsia, a new-onset hypertension with end-organ damage in pregnancy, is associated with maternal death and morbidity, low birthweight, and B cells producing agonistic autoantibodies to the angiotensin II type 1 receptor. Angiotensin II type 1 receptor agonistic autoantibodies are produced during pregnancy and after delivery and are in the fetal circulation of women with preeclampsia. Angiotensin II type 1 receptor agonistic autoantibodies are shown to contribute to endothelial dysfunction, renal dysfunction, hypertension, fetal growth restriction, and chronic inflammation in women with preeclampsia. The reduced uterine perfusion pressure rat model of preeclampsia exhibits these features. In addition, we have shown that the administration of a 'n7AAc', which blocks the actions of the angiotensin II type 1 receptor autoantibodies, improves preeclamptic features in the rat with reduced uterine perfusion pressure. However, the effect of a 'n7AAc' on the long-term health of the offspring of rats with reduced uterine perfusion pressure is unknown. OBJECTIVE: This study aimed to test the hypothesis that inhibition of angiotensin II type 1 receptor autoantibodies during pregnancy will improve offspring birthweight and prevent increased cardiovascular risk in offspring in adulthood. STUDY DESIGN: To test our hypothesis, a 'n7AAc' (24 µg/d) or vehicle (saline) was given on gestation day 14 via miniosmotic pumps to sham-operated (sham) and Sprague-Dawley rat dams with reduced uterine perfusion pressure. Dams were allowed to deliver naturally, and pup weights were recorded within 12 hours after birth. Pups were aged to 16 weeks, at which time mean arterial pressure was measured and whole blood was collected to measure immune cells by flow cytometry, cytokines by enzyme-linked immunosorbent assay, and angiotensin II type 1 receptor autoantibodies by bioassay. A 2-way analysis of variance with the Bonferroni multiple comparison posthoc test was used for statistical analysis. RESULTS: There was no significant change in offspring birthweight of 'n7AAc'-treated male (5.63±0.09 g) or female (5.66±0.14 g) offspring from reduced uterine perfusion pressure dams compared with vehicle male (5.51±0.17 g) or female (5.74±0.13 g) offspring from reduced uterine perfusion pressure dams. In addition, 'n7AAc' treatment did not affect the birthweight of sham male (5.83±0.11 g) or female (5.64±0.12) offspring compared with vehicle sham male (5.811±0.15 g) or female (5.40±0.24 g) offspring. At adulthood, mean arterial pressure was unchanged in 'n7AAc' treated-male (133±2 mm Hg) and female (127±3 mm Hg) offspring from reduced uterine perfusion pressure dams compared with vehicle male (142±3 mm Hg) and female (133±5 mm Hg) offspring from reduced uterine perfusion pressure dams, the 'n7AAc'-treated sham male (133±3 mm Hg) and female (135±3 mm Hg) offspring, and vehicle sham male (138±4 mm Hg) and female (130±5 mm Hg) offspring. The circulating angiotensin II type 1 receptor autoantibodies were increased in vehicle male (10±2 ΔBPM) and female (14±2 ΔBPM) offspring from reduced uterine perfusion pressure dams and 'n7AAc'-treated male (11±2 ΔBPM) and female (11±2 ΔBPM) offspring from reduced uterine perfusion pressure dams compared with vehicle sham male (1±1 ΔBPM) and female (-1±1 ΔBPM) offspring and 'n7AAc'-treated sham male (-2±2 ΔBPM) and female (-2±2 ΔBPM) offspring. CONCLUSION: Our findings indicated that perinatal 7-amino acid sequence peptide treatment does not negatively impact offspring survival or weight at birth. Perinatal 'n7AAc' treatment did not prevent increased cardiovascular risk in offspring, but it also did not cause an increased cardiovascular risk in offspring with reduced uterine perfusion pressure compared with controls. Furthermore, perinatal 'n7AAc' treatment did not affect endogenous immunologic programming as observed by no change in circulating angiotensin II type 1 receptor autoantibodies in either sex of adult offspring from reduced uterine perfusion pressure dams.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Solise D, Campbell N, Ashraf U, et al. Inhibition of angiotensin II type 1 receptor agonistic autoantibodies by direct binding does not impact reduced uterine perfusion pressure offspring birthweight and blood pressure at adulthood. Am J Obstet Gynecol MFM. 2023. PMID: 36990181. doi:10.1016/j.ajogmf.2023.100945

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。